Literature DB >> 25614424

Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease.

Robert S Rosenson1, Shia T Kent2, Todd M Brown3, Michael E Farkouh4, Emily B Levitan2, Huifeng Yun2, Pradeep Sharma2, Monika M Safford3, Meredith Kilgore5, Paul Muntner2, Vera Bittner3.   

Abstract

BACKGROUND: National guidelines recommend use of high-intensity statins after hospitalization for coronary heart disease (CHD) events.
OBJECTIVES: This study sought to estimate the proportion of Medicare beneficiaries filling prescriptions for high-intensity statins after hospital discharge for a CHD event and to analyze whether statin intensity before hospitalization is associated with statin intensity after discharge.
METHODS: We conducted a retrospective cohort study using a 5% random sample of Medicare beneficiaries between 65 and 74 years old. Beneficiaries were included in the analysis if they filled a statin prescription after a CHD event (myocardial infarction or coronary revascularization) in 2007, 2008, or 2009. High-intensity statins included atorvastatin 40 to 80 mg, rosuvastatin 20 to 40 mg, and simvastatin 80 mg.
RESULTS: Among 8,762 Medicare beneficiaries filling a statin prescription after a CHD event, 27% of first post-discharge fills were for a high-intensity statin. The percent filling a high-intensity statin post-discharge was 23.1%, 9.4%, and 80.7%, for beneficiaries not taking statins pre-hospitalization, taking low/moderate-intensity statins, and taking high-intensity statins before their CHD event, respectively. Compared with beneficiaries not on statin therapy pre-hospitalization, multivariable adjusted risk ratios for filling a high-intensity statin were 4.01 (3.58-4.49) and 0.45 (0.40-0.52) for participants taking high-intensity and low/moderate-intensity statins before their CHD event, respectively. Only 11.5% of beneficiaries whose first post-discharge statin fill was for a low/moderate-intensity statin filled a high-intensity statin within 365 days of discharge.
CONCLUSIONS: The majority of Medicare beneficiaries do not fill high-intensity statins after hospitalization for CHD.
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  coronary artery disease; drug use; hydroxymethylglutaryl-CoA reductase inhibitors; secondary prevention

Mesh:

Substances:

Year:  2015        PMID: 25614424     DOI: 10.1016/j.jacc.2014.09.088

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  38 in total

Review 1.  Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association.

Authors:  Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner
Journal:  Circulation       Date:  2017-01-25       Impact factor: 29.690

2.  Effects of statin therapy on platelet reactivity after percutaneous coronary revascularization in patients with acute coronary syndrome.

Authors:  Anna Toso; Stefano De Servi; Mario Leoncini; Dominick J Angiolillo; Paolo Calabrò; Federico Piscione; Marco Cattaneo; Diego Maffeo; Antonio Bartorelli; Cataldo Palmieri; Marco De Carlo; Davide Capodanno; Philippe Genereux; Francesco Bellandi; Chiara Barozzi; Luciana Tomasi; Diego Della Riva; Tullio Palmerini
Journal:  J Thromb Thrombolysis       Date:  2017-10       Impact factor: 2.300

Review 3.  Interventions to improve adherence to lipid-lowering medication.

Authors:  Mieke L van Driel; Michael D Morledge; Robin Ulep; Johnathon P Shaffer; Philippa Davies; Richard Deichmann
Journal:  Cochrane Database Syst Rev       Date:  2016-12-21

4.  Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide.

Authors:  Yashashwi Pokharel; Fengming Tang; Philip G Jones; Vijay Nambi; Vera A Bittner; Ravi S Hira; Khurram Nasir; Paul S Chan; Thomas M Maddox; William J Oetgen; Paul A Heidenreich; William B Borden; John A Spertus; Laura A Petersen; Christie M Ballantyne; Salim S Virani
Journal:  JAMA Cardiol       Date:  2017-04-01       Impact factor: 14.676

5.  Clinical Characteristics and Unmet Need Among Patients with Atherosclerotic Cardiovascular Disease Stratified by Statin Use.

Authors:  Qing Huang; Michael Grabner; Robert J Sanchez; Vincent J Willey; Mark J Cziraky; Swetha R Palli; Thomas P Power
Journal:  Am Health Drug Benefits       Date:  2016-11

6.  Tailored interventions by community pharmacists and general practitioners improve adherence to statins in a Spanish randomized controlled trial.

Authors:  Ainhoa Oñatibia-Astibia; Amaia Malet-Larrea; Belen Larrañaga; Miguel Ángel Gastelurrutia; Begoña Calvo; Dulce Ramírez; Ignacio Cantero; Ángel Garay; Estibaliz Goyenechea
Journal:  Health Serv Res       Date:  2019-04-07       Impact factor: 3.402

7.  Patterns and predictors of lipid-lowering therapy in patients with atherosclerotic cardiovascular disease and/or diabetes mellitus in 2014: Insights from a large US managed-care population.

Authors:  Dylan L Steen; Irfan Khan; Laura Becker; JoAnne M Foody; Katherine Gorcyca; Robert J Sanchez; Robert P Giugliano
Journal:  Clin Cardiol       Date:  2016-12-27       Impact factor: 2.882

8.  Characteristics and Cardiovascular Disease Event Rates among African Americans and Whites Who Meet the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) Trial Inclusion Criteria.

Authors:  Lisandro D Colantonio; Keri L Monda; Robert S Rosenson; Todd M Brown; Katherine E Mues; George Howard; Monika M Safford; Larisa Yedigarova; Michael E Farkouh; Paul Muntner
Journal:  Cardiovasc Drugs Ther       Date:  2019-04       Impact factor: 3.727

9.  Investigation of Motivational Interviewing and Prevention Consults to Achieve Cardiovascular Targets (IMPACT) trial.

Authors:  Eugenia Gianos; Antoinette Schoenthaler; Yu Guo; Judy Zhong; Howard Weintraub; Arthur Schwartzbard; James Underberg; Michael Schloss; Jonathan D Newman; Sean Heffron; Edward A Fisher; Jeffrey S Berger
Journal:  Am Heart J       Date:  2018-01-09       Impact factor: 4.749

10.  Association of Statin Adherence With Mortality in Patients With Atherosclerotic Cardiovascular Disease.

Authors:  Fatima Rodriguez; David J Maron; Joshua W Knowles; Salim S Virani; Shoutzu Lin; Paul A Heidenreich
Journal:  JAMA Cardiol       Date:  2019-03-01       Impact factor: 14.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.